![]() |
市場調查報告書
商品編碼
1384857
介入性心臟器材全球市場規模、佔有率、產業趨勢分析報告:2023-2030 年依應用、產品和地區分類的展望和預測Global Interventional Cardiology Devices Market Size, Share & Industry Trends Analysis Report By End-use (Hospitals & Clinics, Ambulatory Surgical Centers & Others), By Product, By Regional Outlook and Forecast, 2023 - 2030 |
到 2030 年,介入性心臟器材市場規模預計將達到 219 億美元,預測期內CAGR為 7.4%。 2022年市場規模為62,105,000台,成長率為7.3%(2019-2022年)。
根據 KBV Cardinal 矩陣中的分析,雅培實驗室和美敦力公司是介入心臟設備市場的先驅。 Terumo Corporation、Boston Scientific Corporation 和 Teleflex, Inc. 等公司是介入心臟設備市場的主要創新者。 2021 年 9 月,Terumo 與 Etiometry 合作,讓臨床醫師更深入了解病患的病情。
COVID-19 影響分析
在大流行的早期階段,許多擇期和非緊急介入心臟手術被推遲或取消,以優先治療 COVID-19 患者並節省醫療資源。這導致心血管手術和相關設備的使用暫時下降。醫院和醫療機構已將重點轉移到治療急性心肌梗塞(心臟病發作)等緊急、高優先病例。支架、導管和導管導引線等介入性心臟器械的生產和分銷延遲影響了市場。由於需要限制面對面的互動並降低病毒傳播的風險,人們開始關注心臟病患者的遠端監測。因此,COVID-19的爆發對市場產生了溫和的影響。
市場成長要素
心血管疾病盛行率增加
心血管疾病(CVD),如冠狀動脈疾病(CAD)、心臟病和心臟衰竭,仍然是全世界發病和死亡的主要原因。 CVD 的日益普及正在推動對介入性心臟病學手術和設備的需求。心血管疾病是全世界發病和死亡的主要原因之一。數百萬人受到影響,需要診斷和治療的患者數量龐大。隨著世界人口高齡化,與老齡化相關的心血管疾病的發生率也增加。老年人更容易患心血管疾病,增加了對心血管干預措施和設備的需求。全球心血管疾病負擔持續增加,介入心臟設備市場預計將擴大,以滿足不斷成長的醫療保健需求。
人口高齡化比例增加
隨著世界人口高齡化,與老齡化相關的心血管疾病的發生率不斷增加。老年人更有可能需要介入性心臟病學干預,例如置入術和血管成形術。老齡化是冠狀動脈疾病 (CAD)、心臟病、心臟衰竭和心律不整等心血管疾病 (CVD) 的主要危險因子。隨著老齡化,人們更有可能患上這些疾病,從而增加了對介入性心臟病學手術和設備的需求。老齡化與冠狀動脈中動脈粥狀硬化斑塊的進行性累積有關。因此,老年人發生急性冠狀動脈事件(例如心臟病)的風險增加,需要緊急介入。這些技術將推動市場成長,同時增加介入性心臟設備的可用性並改善患者的治療結果和醫療保健效率。
市場抑制因素
高成本、經濟壓力大
然而,介入心臟設備的高成本可能會導致醫療保健預算緊張,並限制獲得先進治療的機會,特別是在資源有限的環境中。平衡創新和承受能力是一個持續的課題。藥物釋放型支架、球囊和診斷成像設備等介入心臟設備的製造和購買成本昂貴。高昂的初期成本可能會導致醫療保健預算緊張,並限制獲得先進治療和技術的機會,特別是在資源有限的地區。監管變化、更新以及指南不斷變化的解釋可能會在核准過程中產生不確定性。監管決策的延遲可能會影響市場進入時間表。
依最終用途分類的展望
依最終用途分類,市場分為醫院和診所、門診手術中心等。 2022 年,門診手術中心在市場上佔了很大的收益佔有率。門診手術中心(ASC)適合進行心導管插入術、血管成形術及支架置入術等微創介入性心臟病手術。患者受益於微創方法,包括更快的恢復時間和更少的術後不適。 ASC 的密集、以患者為中心的環境帶來了更積極和個體化的患者體驗。由於進入門檻比醫院低,病患的焦慮和壓力也減輕了。
產品展望
依產品分類,產品分為冠狀動脈支架、 PTCA球囊導管、附屬器械等。在2022年的市場中, PTCA球囊導管區隔市場將佔重要的收益佔有率。隨著全球冠狀動脈疾病 (CAD) 盛行率的上升,對PTCA球囊導管的需求預計將會成長。由於 CAD 仍然是發病和死亡的主要原因,對血管成形術等介入手術的持續需求正在推動PTCA球囊導管的使用。 PTCA球囊導管是微創血管成形術的重要組成部分,作為傳統心臟直視手術的替代方案越來越受歡迎。由於恢復時間更快和住院時間更短,患者通常更喜歡侵入性較小的方法。 PTCA球囊導管已發展到可以解決更複雜和更困難的病變,例如嚴重鈣化的動脈。針對這種情況設計的專用球囊導管正在擴大可治療的患者範圍。
冠狀動脈支架的前景
冠狀動脈支架市場分為藥物釋放型支架、裸金屬支架和生物可吸收支架。裸金屬支架 (BMS) 領域在 2022 年獲得了巨大的市場收益佔有率。 BMS是一種由不銹鋼或鈷鉻合金製成的金屬支架。不使用藥物塗層。由於缺乏藥物塗層,BMS 通常需要較短持續時間的雙重抗血小板治療 (DAPT)。當延長 DAPT 會增加出血風險時,這會比較有利。
PTCA球囊導管的前景
PTCA球囊導管市場分為常規型、特殊型和藥物塗層型。 2022 年,常規區隔市場獲得了最大的銷售佔有率並主導了市場。介入性心臟病學通常可以改善患者預後、減輕症狀並提高生活品質。它可以恢復心臟的正常血流,緩解胸痛和氣短等症狀。許多介入器械,例如藥物釋放型支架,可以幫助降低血管再阻塞或動脈血管再阻塞的風險,並減少重複介入的需要。微創手術通常可以減輕疼痛、縮短住院時間、更快恢復正常活動並提高患者舒適度。
附屬設備的展望
在輔助設備方面,市場分為 PTCA導管導引線、診斷導管、PTCA引導管和導引鞘。 2022年,PTCA導管導引線部門市場的銷售比重最大。主力導管導引線用於引導冠狀動脈並穿過病變(閉塞或狹窄)以到達血管內的目標部位。為使用其他介入設備(例如球囊導管和支架)提供初始通道和支援。這些導管導引線有助於將導管引導至冠狀動脈內的所需位置。
區域展望
從區域來看,本報告對北美、歐洲、亞太地區和拉丁美洲地區的市場進行了分析。 2022年,亞太地區在市場中獲得了顯著的收益佔有率。亞太地區心血管疾病 (CVD) 的負擔不斷增加,包括冠狀動脈疾病 (CAD)、中風和高血壓。生活方式的改變、都市化和高齡化等因素導致心血管疾病盛行率上升。許多亞太國家的經濟成長導致醫療保健支出增加,從而擴大了醫療保健設施,引進了先進的醫療技術,並改善了介入性心臟病學治療的機會。
The Global Interventional Cardiology Devices Market size is expected to reach $21.9 billion by 2030, rising at a market growth of 7.4% CAGR during the forecast period. In the year 2022, the market attained a volume of 62,100.5 thousand units experiencing a growth of 7.3% (2019-2022).
The drug coating on drug eluting stents (DES) elutes slowly over time, inhibiting tissue growth that can lead to restenosis. This has led to improved long-term outcomes for patients. Consequently, the drug eluting stents segment would generate approximately 53.1% share of the market by 2030. The lower restenosis rates associated with DES have reduced the need for repeat interventions, such as additional angioplasty or stent placement. This translates to improved patient outcomes and reduced healthcare costs. DES has been associated with a lower risk of stent thrombosis (a potentially life-threatening complication), particularly when patients adhere to dual antiplatelet therapy (DAPT).
The major strategies followed by the market participants are Partnerships, Collaborations & Agreements as the key developmental strategy to keep pace with the changing demands of end users. For instance, In June, 2023, Koninklijke Philips N.V. collaborated with Biotronik, to widen the range of cardiovascular devices available for Philips SymphonySuite customers. In January, 2023, Terumo collaborated with Siemens Healthineers, to make better heart care available to more people.
Based on the Analysis presented in the KBV Cardinal matrix; Abbott Laboratories and Medtronic PLC are the forerunners in the Interventional Cardiology Devices Market. Companies such as Terumo Corporation, Boston Scientific Corporation and Teleflex, Inc. are some of the key innovators in the Interventional Cardiology Devices Market. In September 2021, Terumo came into collaboration with Etiometry, to provide clinicians with an in-depth understanding of the patient's condition.
COVID-19 Impact Analysis
During the early stages of the pandemic, many elective and non-urgent interventional cardiology procedures were postponed or canceled to prioritize the treatment of COVID-19 patients and to conserve healthcare resources. This led to a temporary decline in cardiac procedures and reduced use of related devices. Hospitals and healthcare facilities shifted their focus toward treating emergent and high-priority cases, such as acute myocardial infarctions (heart attacks), which continued to require interventional cardiology procedures. Delays in producing and distributing interventional cardiology devices, including stents, catheters, and guidewires, affected the market. With the need to limit in-person interactions and reduce the risk of virus transmission, there was a greater emphasis on remote monitoring of cardiac patients. Thus, the COVID-19 pandemic had a moderate effect on the market.
Market Growth Factors
Increasing prevalence of cardiovascular diseases
Cardiovascular diseases (CVDs) such as coronary artery disease (CAD), heart attacks, and heart failure remain a leading cause of morbidity and mortality globally. The growing prevalence of CVDs drives the demand for interventional cardiology procedures and devices. Cardiovascular diseases are among the leading causes of morbidity and mortality globally. They affect millions of people, resulting in a substantial patient population in need of diagnosis and treatment. As the global population ages, there is a higher incidence of age-related cardiovascular conditions. Older adults are more susceptible to CVDs, increasing the demand for cardiovascular interventions and devices. As the global burden of CVDs continues to increase, the market for interventional cardiology devices is expected to expand to meet the growing healthcare needs.
Rising proportion of the aging population
As the global population ages, there is a higher incidence of age-related cardiovascular conditions. Older adults are more likely to require interventional cardiology interventions, such as stenting and angioplasty. Aging is a major risk factor for cardiovascular diseases (CVDs) such as coronary artery disease (CAD), heart attacks, heart failure, and arrhythmias. Individuals are more likely to develop these conditions as they age, leading to an increased demand for interventional cardiology procedures and devices. Aging is associated with the progressive buildup of atherosclerotic plaques in the coronary arteries. As a result, older individuals are at a higher risk of experiencing acute coronary events, such as heart attacks, which require urgent intervention. These technologies enhance the utilization of interventional cardiology devices, driving market growth while improving patient outcomes and healthcare efficiency.
Market Restraining Factors
High cost and economic pressures
However, the high cost of interventional cardiology devices can strain healthcare budgets and limit access to advanced treatments, especially in resource-constrained settings. Striking a balance between innovation and affordability is a persistent challenge. Interventional cardiology devices, such as drug-eluting stents, balloons, and imaging equipment, can be expensive to manufacture and purchase. The high upfront costs can strain healthcare budgets, limiting access to advanced treatments and technologies, particularly in regions with limited resources. Regulatory changes, updates, or evolving interpretations of guidelines can introduce uncertainty into the approval process. Delays in regulatory decisions can impact market entry timelines.
End-use Outlook
By end-use, the market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The ambulatory surgical centers garnered a significant revenue share in market in 2022. Ambulatory surgical centers (ASCs) are well-suited for minimally invasive interventional cardiology procedures, such as cardiac catheterization, angioplasty, and stent placement. Patients benefit from less invasive approaches, leading to quicker recovery times and reduced post-operative discomfort. The focused and patient-centered environment of ASCs can result in a more positive and personalized patient experience. The setting is often less intimidating than a hospital, which can reduce anxiety and stress for patients.
Product Outlook
By product, the market is categorized into coronary stents, PTCA balloon catheters, accessory devices, and others. The PTCA balloon catheters segment covered a considerable revenue share in the market in 2022. The demand for PTCA balloon catheters is expected to grow in line with the increasing prevalence of coronary artery disease (CAD) globally. As CAD remains a leading cause of morbidity and mortality, there is a continued need for interventional procedures, including angioplasty, which drives the use of PTCA balloon catheters. PTCA balloon catheters are integral to minimally invasive angioplasty procedures, which have gained popularity over traditional open-heart surgeries. Patients often prefer these less invasive approaches because they offer shorter recovery times and reduced hospital stays. PTCA balloon catheters have evolved to address more complex and challenging lesions like heavily calcified arteries. Specialized balloon catheters designed for these situations have expanded the range of treatable patients.
Coronary Stents Outlook
Under coronary stents, the market is segmented into drug eluting stents, bare metal stents, and bioabsorbable stents. The bare metal stents (BMS) segment acquired a substantial revenue share in the market in 2022. BMS are metallic stents made from stainless steel or cobalt-chromium alloys. They do not have drug coating. Due to the absence of a drug coating, BMS typically requires a shorter duration of dual antiplatelet therapy (DAPT). This can be advantageous when extended DAPT poses a higher bleeding risk.
PTCA Balloon Catheters Outlook
Under PTCA balloon catheters, the market is fragmented into normal, specialty, and drug coated. In 2022, the normal segment dominated the market with the maximum revenue share. Interventional cardiology procedures often improve patient outcomes, reduce symptoms, and enhance quality of life. They can help restore normal blood flow to the heart and alleviate chest pain, shortness of breath, and other symptoms. Many interventional devices, such as drug-eluting stents, help reduce the risk of restenosis and re-narrowing of arteries, reducing the need for repeat interventions. Minimally invasive procedures are generally associated with less pain, shorter hospital stays, and a quicker return to normal activities, leading to greater patient comfort.
Accessory Devices Outlook
Under accessory devices, the market is classified into PTCA guidewires, diagnostic catheters, PTCA guiding catheters, and introducer sheaths. In 2022, the PTCA guidewires segment registered the maximum revenue share in the market. Workhorse guidewires are used to navigate through coronary arteries and cross lesions (blockages or stenoses) to reach the target site within the vessel. They provide the initial access and support for delivering other interventional devices, such as balloon catheters and stents. These guidewires help guide catheters to the desired location within the coronary arteries.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region acquired a significant revenue share in the market. Asia Pacific is witnessing a growing burden of cardiovascular diseases (CVDs), including coronary artery disease (CAD), stroke, and hypertension. Factors like lifestyle changes, urbanization, and an aging population contribute to the increased prevalence of CVDs. Economic growth in many Asia Pacific countries has led to increased healthcare spending, enabling the expansion of healthcare facilities, the adoption of advanced medical technologies, and improved access to interventional cardiology procedures.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Medtronic PLC, B. Braun Melsungen AG , Biotronik SE & Co. KG , Cardinal Health, Inc. , Teleflex, Inc. , Koninklijke Philips N.V. ,Alvimedica
Recent Strategies Deployed in Interventional Cardiology Devices Market
Mergers & Acquisition
Feb-2023: Abbott Laboratories took over Cardiovascular Systems, Inc., a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. The acquisition of CSI enhances Abbott's vascular device offerings portfolio.
Aug-2022: Medtronic completed the acquisition of Affera, a US-based developer of medical devices. The acquisition of Affera broadens the acquiring company's cardiac ablation platform.
Feb-2022: Boston Scientific completed the acquisition of Baylis Medical Company, a Canada-based developer of medical devices. This acquisition enables the acquiring company to incorporate Baylis' platforms within its existing electrophysiology and structural heart offerings, thereby reinforcing its market position.
Product Launches and Product Expansions
Aug-2022: Medtronic PLC launched the Onyx Frontier drug-eluting stent (DES), the Onyx Frontier DES is employed in the management of individuals suffering from coronary artery disease (CAD), a condition resulting from the accumulation of plaque within the coronary arteries. The Onyx Frontier drug-eluting stent (DES) features matrix sizes ranging from 2.0mm to 5.0mm diameters, with the expandability of sizes from 4.50-5.00mm.
Jul-2021: Medtronic PLC introduced the Prevail drug-coated balloon (DCB) Catheter. The Prevail DCB employs a fast-absorbing drug, paclitaxel, to facilitate the treatment of de novo lesions, small vessel disease, and in-stent restenosis (ISR). The Prevail DCB would be utilized in percutaneous coronary intervention (PCI) procedures to address narrowed or obstructed coronary arteries in patients diagnosed with coronary artery disease (CAD).
Partnerships, Collaborations & Agreements
Jun-2023: Koninklijke Philips N.V. collaborated with Biotronik, a multi-national cardiovascular biomedical research and technology company. This collaboration aimed to widen the range of cardiovascular devices available for Philips SymphonySuite customers.
Jan-2023: Terumo collaborated with Siemens Healthineers, a medical technology company. The collaboration focuses on reinforcing cardiac care in India. This collaboration aims at making better heart care available to more people.
Sep-2021: Terumo came into collaboration with Etiometry, a US-based provider of clinic decision-support software. The collaboration involves introducing clinical decision support to cardiac surgery patients. Integrating Etiometry's platform with the surgical devices company's devices would provide clinicians with an in-depth understanding of the patient's condition.
Mar-2021: Braun Interventional Systems joined hands with Infraredx, designs, develops, manufactures, and distributes medical devices. Together the companies aimed to boost the FDA investigational device exemption clinical test for the SeQuent Please ReX drug coated PTCA balloon catheter. Additionally, The SeQuent Please ReX drug-coated PTCA balloon catheter is developed to cure coronary in-stent restenosis, or the incremental re-narrowing of a coronary artery following stent transplantation.
Approvals
May-2022: Medtronic PLC received FDA approval for the Onyx Frontier drug-eluting stent (DES). Onyx Frontier DES is aimed at the care of individuals afflicted with coronary artery disease (CAD), a condition initiated by the accumulation of plaque within the coronary artery walls.
Feb-2022: Medtronic plc received a U.S. Food and Drug Administration approval for Freezer and Freezer Xtra Catheters for the treatment of paediatric Atrioventricular Nodal Re-entrant Tachycardia. Catheter ablation is resilient, one-use equipment used to freeze cardiac tissue and block unnecessary electrical signals within the heart. Additionally, Freezer and Freezer Xtra are the first-line antidote for the treatment of AVNRT.
Market Segments covered in the Report:
By End-Use (Volume, Thousand Units, USD Million, 2019-2030)
By Product (Volume, Thousand Units, USD Million, 2019-2030)
By Geography (Volume, Thousand Units, USD Million, 2019-2030)
Companies Profiled
Unique Offerings from KBV Research